Belite Bio Inc ADR

Belite Bio, Inc. is a clinical-stage biopharmaceutical drug development company focused on researching and developing novel therapeutics for unmet medical needs in the United States. Its lead product candidate, Tinlarebant (LBS-008), is an orally administered therapy in Phase 3 clinical trials as an early intervention to maintain the health and integrity of retinal tissues in patients with Stargardt disease type 1 and geographic atrophy. The company is also developing LBS-009, an oral retinol-binding protein 4 therapy in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc. was founded in 2016 and is based in San Diego, California. It operates as a subsidiary of Lin Bioscience International Ltd.